Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Consolidated Net Income (2022 - 2026)

TriSalus Life Sciences has reported Consolidated Net Income over the past 5 years, most recently at $1.5 million for Q1 2026.

  • For Q1 2026, Consolidated Net Income rose 114.83% year-over-year to $1.5 million; the TTM value through Mar 2026 reached -$27.3 million, changed 0.36%, while the annual FY2025 figure was -$39.2 million, 30.56% down from the prior year.
  • Consolidated Net Income for Q1 2026 was $1.5 million at TriSalus Life Sciences, up from -$9.8 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $2.8 million in Q1 2022 and troughed at -$35.6 million in Q4 2023.
  • A 5-year average of -$9.0 million and a median of -$8.3 million in 2025 define the central range for Consolidated Net Income.
  • Biggest five-year swings in Consolidated Net Income: tumbled 685.61% in 2023 and later skyrocketed 114.83% in 2026.
  • Year by year, Consolidated Net Income stood at -$22.5 million in 2022, then crashed by 58.1% to -$35.6 million in 2023, then soared by 71.64% to -$10.1 million in 2024, then grew by 3.51% to -$9.8 million in 2025, then surged by 115.78% to $1.5 million in 2026.
  • Business Quant data shows Consolidated Net Income for TLSI at $1.5 million in Q1 2026, -$9.8 million in Q4 2025, and -$10.8 million in Q3 2025.